8-K: Precigen Reports Strong PAPZIMEOS Launch, Targets 2026 Cash Flow Break-Even

Precigen announced full year 2025 financial results, highlighting the successful US launch of PAPZIMEOS and a strategic path to cash flow break-even by the end of 2026.

Summary

• Precigen transitioned to a commercial-stage company with the US FDA approval of PAPZIMEOS (zopapogene imadenovec-drba) in August 2025, the first-and-only approved treatment for adults with Recurrent Respiratory Papillomatosis (RRP).
• PAPZIMEOS generated $3.4 million in net product revenue in the fourth quarter of 2025, representing its first partial quarter of US commercial sales.
• The Centers for Medicare and Medicaid Services (CMS) assigned a permanent J-code, J3404, to PAPZIMEOS, effective April 1, 2026, which is expected to streamline claims processing and facilitate broader patient access.
• The Marketing Authorization Application for PAPZIMEOS for the treatment of adults with RRP was validated by the European Medicines Agency (EMA) and is currently under review.
• Cash, cash equivalents, and investments totaled $100.4 million as of December 31, 2025, which is expected to fund the Company's operations to cash flow break-even by the end of 2026.
• Total revenues increased by $5.8 million compared to the year ended December 31, 2024, primarily driven by PAPZIMEOS product revenue and higher collaboration and licensing revenue.
• Net loss attributable to common shareholders was $429.6 million, or $1.37 per basic and diluted share, for 2025, significantly higher than the $126.2 million, or $0.47 per share, in 2024, largely due to non-cash items.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report due to the successful commercial launch of PAPZIMEOS, strong market adoption, and a clear path to cash flow break-even, despite a significant non-cash driven net loss increase.

Positives

• Successful US FDA approval and launch of PAPZIMEOS in August 2025, marking the Company's transition to a commercial-stage entity.
• PAPZIMEOS generated $3.4 million in net product revenue in its first partial quarter of US commercial sales (Q4 2025), with strong momentum continuing into Q1 2026.
• A permanent J-code (J3404) has been assigned to PAPZIMEOS by CMS, effective April 1, 2026, which will streamline reimbursement and expand patient access.
• The Marketing Authorization Application for PAPZIMEOS has been validated by the EMA and is under review, indicating potential for European market entry.
• An expert consensus paper, sponsored by the RRP Foundation, recommended PAPZIMEOS as the new standard of care first-line treatment for adults with RRP in the US.
• Cash, cash equivalents, and investments of $100.4 million as of December 31, 2025, are projected to fund operations to cash flow break-even by the end of 2026.
• Total revenues increased by $5.8 million year-over-year, driven by PAPZIMEOS sales and increased collaboration and licensing revenue.
• Research and development expenses decreased by $11.7 million (22.1%) compared to the prior year, reflecting strategic pipeline prioritization and the closure of ActoBio operations.
• Patient hub enrollment for PAPZIMEOS has surpassed 300 registered patients, demonstrating substantial patient and physician demand.
• Payer coverage for PAPZIMEOS now extends to approximately 215 million US lives, covering about 90% of insured individuals, including Medicare and Medicaid.
• All outstanding Preferred Shares were converted into common shares on September 15, 2025.

Negatives

• Net loss attributable to common shareholders significantly increased to $429.6 million ($1.37 per share) for the year ended December 31, 2025, compared to $126.2 million ($0.47 per share) in 2024.
• The increase in net loss was primarily driven by non-cash items, including a $139.5 million increase in the fair value of warrant liabilities and a $179.0 million non-cash deemed dividend on preferred stock.
• Selling, General and Administrative (SG&A) expenses increased substantially by $28.8 million (69.8%) compared to the prior year, due to significant investments in PAPZIMEOS commercial readiness.
• Total other income (expense), net, shifted from an income of $7.0 million in 2024 to an expense of $140.1 million in 2025, largely due to the change in fair value of warrant liabilities.

Risks

• Actual results could differ materially from forward-looking statements due to numerous risks and uncertainties.
• Uncertainties exist regarding the success of efforts to commercialize PAPZIMEOS, including the revenue expected from such efforts.
• Risks are associated with the Company's ability to successfully obtain foreign regulatory approvals for PAPZIMEOS.
• Uncertainties exist regarding the safety and efficacy of PAPZIMEOS and its ability to treat RRP.
• Risks are related to the Company's future financial and operational results, including its ability to reach cash flow break-even.
• Uncertainties exist regarding the Company's ability to commence or complete ongoing clinical studies for its clinical and pre-clinical stage candidates.

Future Outlook

Precigen anticipates continued strong momentum for PAPZIMEOS sales in the first quarter of 2026 and expects its current cash position and anticipated PAPZIMEOS sales to fund operations to cash flow break-even by the end of 2026. The company is also pursuing European market authorization for PAPZIMEOS and continuing clinical trials for PRGN-2009 in HPV-associated cancers.

Management Comments

• "2025 marked a transformational year for Precigen as we transitioned from a clinical-stage to a commercial-stage company and recognized our first commercial product revenues toward the end of the year." Helen Sabzevari, PhD, President and CEO.
• "We are seeing strong alignment within the physician community around PAPZIMEOS as the first-line standard of care for adults with RRP, supported by its profile as the only approved therapy for RRP, the compelling safety and efficacy data, and the encouraging durability of response observed to date." Helen Sabzevari, PhD, President and CEO.
• "Commercialization of PAPZIMEOS continues to move rapidly, with growing physician adoption and patient uptake since approval in August." Phil Tennant, Chief Commercial Officer.
• "Based upon our present forecast, we expect our current cash position and anticipated cash to be received from PAPZIMEOS sales will fund operations through cash flow break-even by the end of 2026, representing a strong financial foundation as we continue to execute on our commercial and strategic objectives." Harry Thomasian Jr., Chief Financial Officer.

Industry Context

StockSavvy.ai notes that Precigen's successful transition to a commercial-stage company with PAPZIMEOS approval and initial sales positions it favorably in the rare disease biopharmaceutical market. The rapid physician adoption and strong patient demand, coupled with a permanent J-code and EMA review, suggest a robust market entry for a first-in-class therapy, potentially setting a new standard of care in the RRP treatment landscape. The focus on cash flow break-even by late 2026 is a critical milestone for emerging biotechs post-commercialization, indicating a move towards financial self-sufficiency.

Comparison to Industry Standards

• PAPZIMEOS is the first-and-only FDA-approved treatment for adults with RRP, establishing a new standard of care and differentiating it significantly from previous off-label or surgical approaches, similar to how other orphan drugs address highly unmet medical needs.
• The rapid payer coverage extending to approximately 90% of insured US lives (215 million) within months of launch is a strong indicator of market acceptance and commercial team effectiveness, comparable to successful rare disease drug launches by companies like Vertex Pharmaceuticals (e.g., Trikafta for cystic fibrosis) or BioMarin Pharmaceutical (e.g., Voxzogo for achondroplasia) which often achieve broad coverage due to high unmet need.
• The assignment of a permanent J-code (J3404) by CMS, effective April 1, 2026, is a standard but crucial step for physician-administered therapies, similar to how other specialty drugs (e.g., oncology biologics from Amgen or Genentech) secure streamlined reimbursement, facilitating broader access and consistent billing.
• The target of reaching cash flow break-even by the end of 2026, following a major product launch, is an ambitious but achievable goal for a commercial-stage biotech, often seen in companies like Sarepta Therapeutics post-Duchenne muscular dystrophy drug approvals, demonstrating a clear path to financial sustainability.

Stakeholder Impact

• Shareholders: Potential for increased value due to successful product launch, market expansion, and projected cash flow break-even, but diluted by increased net loss and share count from non-cash items.
• Patients (RRP): Significant positive impact with the availability of PAPZIMEOS as the first FDA-approved treatment, offering a new standard of care and improved quality of life.
• Healthcare Providers: Streamlined reimbursement process for PAPZIMEOS with the new J-code, facilitating easier prescription and administration.
• Employees: Continued focus on commercialization and pipeline development suggests stability and growth opportunities within the company.
• Payer/Insurers: Increased coverage for PAPZIMEOS indicates acceptance of its value proposition for RRP treatment, potentially leading to higher healthcare costs but improved patient outcomes.

Next Steps

• Continue building strong momentum for PAPZIMEOS US commercial sales, with a significant increase in demand already observed in Q1 2026.
• Utilize the permanent J-code (J3404) for PAPZIMEOS, effective April 1, 2026, to streamline claims and facilitate broader patient access.
• Advance the Marketing Authorization Application for PAPZIMEOS through the European Medicines Agency (EMA) review process.
• Continue the open-label redosing study (NCT06538480) to evaluate safety, vector shedding, and retreatment efficacy of zopapogene imadenovec in adults with RRP.
• Continue Phase 2 clinical trials for PRGN-2009 AdenoVerse Immunotherapy in newly diagnosed HPV-associated oropharyngeal cancer under a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI).
• Continue Phase 2 clinical trial for PRGN-2009 in combination with pembrolizumab in recurrent/metastatic cervical cancer.
• Work towards achieving cash flow break-even by the end of 2026.
• Host a conference call on March 25, 2026, at 4:30 PM ET to discuss full year 2025 financial results and provide further substantive updates on commercial progress for the first quarter of 2026.

Key Dates

Recommendation

While the successful commercial launch of PAPZIMEOS, strong market adoption, and a clear path to cash flow break-even by late 2026 are significant positives, the substantial increase in net loss, primarily driven by non-cash items related to warrant liabilities and preferred stock, introduces a degree of financial volatility. The company is in a critical transition phase, and while the commercial progress is encouraging, the financial results reflect the costs of this transition. A 'hold' recommendation allows investors to observe the continued commercial ramp-up and the company's progress towards its cash flow break-even target without committing further capital until the financial picture stabilizes and the non-cash impacts are fully absorbed.

Keywords

Precigen, PGEN, PAPZIMEOS, RRP, Recurrent Respiratory Papillomatosis, Biopharmaceutical, FDA Approval, Commercial Launch, Financial Results, Zopapogene Imadenovec, Orphan Drug, Immunotherapy, HPV-associated cancers, PRGN-2009, Cash Flow Break-even, EMA Review, J-code